Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karlheinz Stegmeier is active.

Publication


Featured researches published by Karlheinz Stegmeier.


Annals of the New York Academy of Sciences | 1982

THE SHORT- AND LONG-TERM EFFECTS OF BEZAFIBRATE IN THE RAT*

H. Dariush Fahimi; Andreas Reinicke; Martin Sujatta; Sadaki Yokota; Muhsin Özel; Franz Hartig; Karlheinz Stegmeier

Bezafibrate is a potent hypolipidemic agent, which causes marked proliferation of peroxisomes in rat liver. At the same dosage, bezafibrate is more effective in male than in female rats. This is probably related to divergent pharmacokinetics, which cause differences in drug level in serum and liver. The volume density of peroxisomes and several of their enzymes such as carnitine acetyl transferase and acyl-COA oxidase increase in a dose-related fashion. The hypolipidemic effect of bezafibrate, however, does not correlate with the used dosage. This implies that peroxisomal proliferation may play only a minor role in the hypolipidemic action of bezafibrate. In animals treated for 26 months with 300, 750, or 1500 ppm bezafibrate, the relative liver weight and serum triglycerides did not differ significantly from controls. Peroxisomal proliferation varied in different cells, being most prominent in single hepatocytes. The liver catalase activity was significantly reduced, but carnitine acetyl transferase was increased. Abnormal peroxisomes and mitochondria with longitudinal cristae were quite frequent. In one focus, catalase activity was severely diminished ahd peroxisomes were markedly reduced. The incidence of liver tumors was the same (1-3%) in treated animals as in controls.


Thrombosis Research | 1984

The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug

Karlheinz Stegmeier; Johannes Dr. Rer. Nat. Dr. Med. Pill; B. Müller-Beckmann; Felix Helmut Schmidt; E.C. Witte; Hans Peter Dr Rer Nat Wolff; Heinrich Patscheke

BM 13.177 (4-[2-(benzenesulfonamido)-ethyl]-phenoxyacetic acid) is a representative of a new class of sulfonamidophenylcarboxylic acids which possess platelet-inhibitory and anti-thrombotic activity and inhibits the contraction of rabbit aorta stimulated by PG endoperoxides and TXA2. BM 13.177 5 mg/kg body weight p.o. protected rabbits from arachidonate-induced sudden death and greater than or equal to 10 mg/kg dose-dependently reduced the experimental thrombus formation induced in the rabbit aorta by perivascular administration of silver nitrate. In guinea-pigs, the collagen-induced bronchoconstriction was inhibited in a dose- and time-dependent fashion. The formation of TXA2 and the TXA2-induced platelet aggregation and smooth muscle contraction are probably crucial events in these experimental models. The protective effect of BM 13.177 may, therefore, be due to the TXA2-antagonizing effect of BM 13.177, which has been conclusively demonstrated in human platelets (PATSCHEKE and STEGMEIER, Thrombosis Res., 33, 277-288 (1984). The antagonism of TXA2 is supported by the observation that BM 13.177 also specifically inhibits the contraction of isolated arterial strips from rabbits which were stimulated with the thromboxane A2 mimetic U 46619. Schild-plot with a slope close to unity suggests a competitive type of antagonism. BM 13.177 exhibited neither anti-inflammatory nor ulcer-inducing activity of cyclooxygenase inhibitors. Furthermore it did not block the TXB2 formation in spontaneously clotting blood from rabbits and did not inhibit the release of prostacyclin-like activity from rabbit aortas. The lack of toxicological effects in long-term toxicity studies in rat and dog, together with the absence of objective and subjective side effects in the first human studies have encouraged us to initiate clinical trials in order to evaluate the therapeutic benefit of this new approach in humans.


Biochemical Pharmacology | 1986

The effects of BM 15.766, an inhibitor of 7-dehydrocholesterol δ7-reductase∗, on cholesterol biosynthesis in primary rat hepatocytes

Johannes Dr Aufenanger; Johannes Pill; Felix Helmut Schmidt; Karlheinz Stegmeier

The effect of the piperazine derivative BM 15.766 (4-(2-[1-(4-chlorocinnamyl)piperazin-4-yl]ethyl]-benzoic acid) on the biosynthesis of sterols was investigated in adult rat hepatocytes in primary monolayer culture. The substance led to a dose-dependent reduction of cholesterol in the serum of various species of animals such as rat, dog and marmoset. BM 15.766 showed a dose-dependent action on the incorporation of 14C-acetate in neutral, nonsaponifiable lipids. The inhibition of the overall incorporation was 10-12% (10(-5) M). No inhibition was observed in the hepatocytes over the entire dose range of 10(-8) M to 2 X 10(-5) M, while the release of the neutral lipids from the hepatocytes into the culture medium was reduced by up to 40%. The biosynthesis of cholesterol could be reduced by more than 90%. Simultaneously, 7-dehydrocholesterol levels rose in the cells and, to a less marked extent, in the medium. This can be interpreted as an indication that 7-dehydrocholesterol is incorporated into the cell membrane, which results in a lower release of 7-dehydrocholesterol into the medium in comparison with controls. The site of attack is the inhibition of the delta 5.7-sterol delta 7-reductase. The formation of desmosterol and cholestatrienol as well as other 7-dehydrocholesterol precursors could also be demonstrated. After longer incubation, there was an additional accumulation of squalene and lanosterol with simultaneous reduction of 7-dehydrocholesterol by BM 15.766, whereas the total 14C-acetate incorporation in neutral lipids was increased.


Fresenius Journal of Analytical Chemistry | 1987

Thin-layer chromatography of radioactively labelled cholesterol and precursors from biological material

Johannes Dr. Rer. Nat. Dr. Med. Pill; Johannes Dr Aufenanger; Karlheinz Stegmeier; Felix Helmut Schmidt; D. Müller

SummaryThe investigation methods of the action of xenobiotics on sterol biosynthesis from 14C-acetate in rat hepatocyte cultures can be developed, with regard to extraction using Extrelut and the separation of the sterol pattern by thin-layer chromatography, in such a way that they are suitable for wider application, e.g., screening. Good visualisation and recognition of changes in the sterol pattern are possible using autoradiography of the thin-layer chromatogram.


Cytotechnology | 1988

In vitro test system for compounds affecting cholesterol pathway: Studies in primary rat liver cell cultures

Johannes Pill; Johannes Dr Aufenanger; Barbara Frey; Albrecht Frey; Gisela Johne; Karlheinz Stegmeier

Rat liver cells derived from male and female animals in primary monolayer cultures were investigated for suitability as a test system for xenobiotics affecting the cholesterol pathway. An appropriate mode of extraction and separation of newly formed cholesterol and precursors is described. This system can be widely applied.Rat liver cells from females in oestrus cycle had a higher synthesis rate of cholesterol than those from males. The disadvantages related to the cycle phases make male rats more appropriate donor animals for the test system developed. The altered in vitro cholesterol synthesis is relevant to that in vivo.The extraction of newly synthesized cholesterol and its precursors by means of columns packed with large-pore kieselgur is precise and time saving. The modified separation by thin-layer chromatography on silica gel layers impregnated with silver nitrate enables direct separation from the extract and is sufficient to recognize cholesterol and its precursors.The method in this form is suitable for processing a large number of specimens e.g. for screening.


Archive | 1993

Pharmacological inhibition of atherosclerosis in diet-induced and genetically hypercholesterolemic rabbits

Johannes Pill; S. Wolff; L. Dörge; Karlheinz Stegmeier; F. Hartig; J. Metz

Daltroban verminderte die Atherosklerose bei Kaninchen mit sowohl einer futterinduzierten als auch einer genetischen Hypercholesterinamie. Dies zeigt, das die antiatherosklerotische Wirkung von Daltroban unabhangig von der Art der Hypercholesterinamie ist. Unter beiden Versuchsbedingungen ist die Plattchenaggregation unter Daltroban deutlich gehemmt. Dies und die Reduktion der Cholesterylesterakkumulation auf zellularer Ebene [11] konnten zum antiatherosklerotischen Effekt von Daltroban beitragen.


Archive | 1982

Sulphonamidophenylcarboxylic acid compounds and pharmaceutical compositions containing them

Ernst-Christian Witte; Hans P. Wolfe; Karlheinz Stegmeier; Egon Roesch


Archive | 1979

Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition

Ernst-Christian Witte; Hans Peter Dr Rer Nat Wolff; Max Dr Rer Nat Thiel; Karlheinz Stegmeier; Egon Roesch


Archive | 1994

New 4-aminopyridines, process for preparing the same and medicaments containing the same

Der Saal Wolfgang Von; Reinhard Heck; Herbert Leinert; Thomas Poll; Karlheinz Stegmeier; Helmut Michel


Annals of the New York Academy of Sciences | 1982

STUDY OF LIVER ENZYMES: PEROXISOME PROLIFERATION AND TUMOR RATES IN RATS AT THE END OF CARCINOGENICITY STUDIES WITH BEZAFIBRATE AND CLOFIBRATE

Franz Hartig; Karlheinz Stegmeier; Gottfried Hebold; Muhsin Özel; H. Dariush Fahimi

Collaboration


Dive into the Karlheinz Stegmeier's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge